I agree. I assume that this is the type on information that typically would not be disclosed and thus, no word from Cytodyn.
Information sneaks out that would not be released publicly by a company. Dr. Patterson said early in CD10 and Cd12 trials that they were seeing "interesting" patterns with the patients, supporting the argument another physician made that Cytodyn likely could know which patients received leronlimab simply based on rapid correction of abnormal lab tests (similar statement ascribed to a nurse in one of the Samantha Moffett interviews).
I believe that there is a substantive reason for NP's apparently over-rosy forward looking discussion of upcoming result.